Pinealon: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. Pinealon is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

Objective: Provide dose–response data for Pinealon (Glu‑Asp‑Arg) from animal studies, including body‑weight adjusted doses, regimens, and outcomes.

Summary of available evidence

• Aged rat ischemia/reperfusion model (bilateral carotid artery occlusion). Pinealon was administered intraperitoneally at 10 µg/kg once daily for five days prior to surgery. This preventive regimen increased survival after occlusion (treated vs. control at 3/12/24 h: 90%/90%/85% vs. 70%/60%/40%), altered behavior in open‑field testing (increases in behavioral sleep and relaxed wakefulness with concurrent decreases in orienting/motivational behavior and locomotor activity), and modulated caspase‑3 activity (in sham animals, increases of ~34% in cortex and ~27% in brainstem; when given prior to occlusion, reductions vs. occlusion controls of ~48% in cortex [p=0.02] and ~24% in brainstem [p=0.04]). Only a single dose level (10 µg/kg i.p.) and schedule were reported in the accessible text; no multi‑dose comparison within this study was presented. Species/age/model: male rats, 16 months old; route: intraperitoneal; schedule: daily ×5 pre‑injury; outcomes: survival, behavior, caspase‑3 activity.

Limitations and notes

• Within the retrieved and analyzable texts, we found only one in vivo animal study with explicit per‑kg dosing and regimen details for Pinealon. No formal dose‑response (multiple doses) was reported; thus, the evidence provides a single‑point reference dose (10 µg/kg i.p. ×5 days pre‑insult) and associated outcomes rather than a dose–response curve.

Embedded summary table

• Additional animal studies (e.g., in diabetic models or other CNS injury paradigms) were referenced in searches but either were inaccessible in full or lacked extractable in vivo dosing details in the provided excerpts; therefore, they are not summarized here. Future retrieval of those full texts could yield more dosing data, including potential multi‑dose evaluations.

Administration Routes#

Oral route. For ultrashort peptides, oral exposure is typically limited by luminal and brush-border peptidases, variable gastric transit, and intracellular hydrolysis after PEPT1 uptake; only a fraction may exit intact to blood, plausibly via LAT-family carriers. Empirical data from a model dipeptide show very low systemic levels after tens of milligrams orally (nanomolar Cmax), consistent with oral bioavailability often <1% for small hydrophilic peptides and substantial interindividual variability. After any absorption, rapid renal filtration and serum peptidases favor short half-lives. These principles imply Pinealon’s oral bioavailability is likely very low and variable without formulation/enhancers, with Tmax governed by gastric emptying and intestinal transit and t1/2 short due to renal/enzymatic clearance.

Subcutaneous and intramuscular routes. SC and IM administration circumvent first-pass metabolism and gastrointestinal degradation, leading to greater and more reliable systemic exposure than oral for peptides of similar size. Absorption proceeds from interstitial space into capillaries/lymph, giving relatively rapid onset; however, once in plasma, ultrashort peptides are still cleared quickly by peptidases and renal filtration, yielding short half-lives. Specific Pinealon Tmax/Cmax/half-life after SC or IM were not identified; nonetheless, general peptide delivery literature supports higher bioavailability and lower variability for non-oral routes compared with oral, with exposure primarily limited by systemic clearance rather than absorption.

Topical route. Passive transdermal permeation of small, hydrophilic, charged tripeptides like EDR is expected to be poor due to the stratum corneum barrier; appreciable systemic bioavailability is unlikely without penetration enhancers, physical methods (microneedles/iontophoresis), or specialized carriers. Any local epidermal uptake could involve epithelial peptide transporters, but quantitative skin permeation and systemic PK are not demonstrated. Consequently, topical delivery of Pinealon is expected to yield minimal systemic exposure; route utility would be limited to local effects unless enhanced-delivery technologies are used.

Distribution and BBB. LAT1 is expressed at the BBB and in multiple tissues. Computational analyses suggest EDR may bind LAT1, raising a plausible mechanism for CNS access after systemic dosing; PEPT2 expression in choroid plexus and kidney further suggests roles in CSF handling and renal reabsorption, respectively. However, no in vivo pharmacokinetic demonstrations of Pinealon’s brain exposure, distribution volume, or CSF kinetics were found; competition from endogenous substrates and rapid clearance are likely constraints.

Route-specific comparative conclusions.

• Oral: Expected very low and variable bioavailability; Tmax driven by GI transit; short systemic half-life from rapid renal/enzymatic clearance; potential but limited transporter-mediated intestinal uptake via PEPT1 and basolateral export via LAT. Overall, lowest systemic exposure among routes without formulation strategies.
• Subcutaneous: Avoids first-pass and GI degradation; relatively complete absorption possible; higher and less variable exposure than oral; rapid systemic clearance still yields short half-life; practical route for systemic effects if frequent dosing or modified-release formulations are acceptable.
• Intramuscular: Similar to SC with potentially faster absorption for some formulations/muscle sites; systemic exposure greater than oral; clearance constraints identical to SC; no Pinealon-specific kinetics located.
• Topical: Minimal passive systemic absorption expected; mainly suited for local delivery unless enhanced by physical/chemical methods; systemic PK data lacking.

Evidence gaps. We found no direct Pinealon (EDR) human or animal PK studies reporting absolute bioavailability, Tmax, Cmax, half-life, distribution, or excretion by SC, IM, oral, or topical routes. Current inferences rely on transporter biology and peptide PK principles and should be tested with dedicated studies.

Human-Equivalent Dosing#

Summary The accessible Pinealon (EDR; Glu–Asp–Arg) literature describes mechanistic and in vitro concentration ranges and notes animal and clinical contexts, but it does not report explicit animal-to-human dose scaling or human-equivalent dose (HED) calculations for Pinealon itself. In the absence of Pinealon-specific scaling examples, general interspecies allometric approaches used broadly for drugs and small peptides are summarized, including body-surface-area (BSA) scaling with Km factors, pharmacokinetically guided AUC×CL approaches, minimal anticipated biological effect level (MABEL), and PK–PD modeling; these are documented in regulatory-aligned reviews and can be applied if in vivo Pinealon dose/exposure data are available (e.g., NOAEL, AUC).

What the Pinealon literature shows about dosing

• Identity and context: Pinealon is the ultrashort tripeptide EDR (Glu–Asp–Arg) with neuroprotective activity. Reports emphasize molecular mechanisms (e.g., effects on MAPK/ERK signaling, ROS, histone interactions) and demonstrate in vitro concentrations (e.g., 20–200 ng/mL) restoring spine density in neuronal cultures, and narratives of oral use in patients, but do not provide explicit in vivo animal dose values or HED translations in the accessible text.
• Consequence: Because explicit Pinealon animal dose levels and their translation to human doses are not reported in these sources, no Pinealon-specific allometric scaling examples can be cited from them.

Allometric scaling methods used in the literature (general, applicable to small peptides)

• BSA (Km) scaling per FDA-aligned practice: Convert animal dose (mg/kg) to HED (mg/kg) via species-specific Km factors: HED (mg/kg) = Animal dose (mg/kg) × (Km_animal / Km_human). Standard Km examples: human 37, rat 6, mouse 3, dog 20. Equivalently, a weight-exponent form can be used, e.g., HED (mg/kg) = Animal dose (mg/kg) × (Weight_animal/Weight_human)^(1−b), with b commonly 0.67 for conventional drugs. Worked examples and conversions to/from mg/m^2 are provided. • Practical multipliers from Km ratios: rat→human ≈ 6/37 ≈ 0.162; mouse→human ≈ 3/37 ≈ 0.081; dog→human ≈ 20/37 ≈ 0.541. Thus, a rat dose of D mg/kg corresponds to HED ≈ 0.162·D mg/kg, etc. These are the standard calculations used to derive conservative HEDs from NOAELs before applying safety factors.
• Pharmacokinetically guided approach (AUC×CL): Identify the NOAEL-associated exposure (AUC) in the most sensitive species and multiply by predicted human clearance to estimate an initial human dose; apply safety factors thereafter. Example framework: Human dose (mg) ≈ AUC_NOAEL(animal) × CL_human, acknowledging assumptions and limitations.
• MABEL approach: Start from the minimal anticipated biological effect level based on in vitro/in vivo pharmacology, convert to HED using allometry, then apply safety factors; often preferred for biologics or when pharmacology is very potent.
• PK–PD modeling: Build interspecies PK–PD models (incorporating predicted human PK such as clearance and volume) to simulate exposure–response and select a starting human dose; resource-intensive and data-dependent.

What has been used specifically for Pinealon?

• Within the accessible Pinealon (EDR) publications reviewed, authors do not describe applying BSA/Km, AUC×CL, MABEL, or PK–PD to translate Pinealon animal doses to HED; the reports are mechanistic and in vitro focused, and do not present explicit in vivo dose-scaling calculations.

Implications for practice

• If one needs to scale a Pinealon animal dose to an HED, in the absence of Pinealon-specific guidance, the standard BSA (Km) method provides a conservative, regulator-recognized starting point. Example: For a rat dose D mg/kg, HED ≈ 0.162·D mg/kg; for a mouse dose D mg/kg, HED ≈ 0.081·D mg/kg; further divide by a safety factor (commonly ≥10) to derive a maximum recommended starting dose for first-in-human studies. Alternatively, if animal exposure (AUC) at NOAEL and a predicted human clearance are known, a PK-guided AUC×CL estimate can be used, again with safety factors and pharmacology considered via MABEL/PK–PD as appropriate.

Evidence limitations

• The present Pinealon sources do not disclose explicit animal in vivo dose levels or author-stated scaling methods, so the Pinealon-specific part of this answer is necessarily limited to stating that no such scaling was reported in the accessible texts. General allometric methodologies are provided for completeness and applicability should suitable Pinealon in vivo dose/exposure data be obtained.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• Pinealon overview and research guide
• Pinealon side effects profile
• Pinealon research evidence